FRAXA's Impact to Date

$
0
32,306,347

Direct Investment in Fragile X Research

0
4

ONGOING FRAGILE X CLINICAL TRIALS AND STUDIES

Current Clinical Trials
0
41

TEAMS ACTIVELY RESEARCHING FRAGILE X

Current Research Grants
0
2

GENE THERAPY AND PROTEIN REPLACEMENT STUDIES

Current Studies
0
31

PHARMACEUTICAL AND BIOMEDICAL PARTNERS

0
618

RESEARCH GRANTS AWARDED

0
19

COUNTRIES ARE HOME TO RESEARCH TEAMS

What is Fragile X Syndrome?

Fragile X syndrome (FXS) is the most common inherited cause of autism and intellectual disabilities. It affects 1 in 4,000 boys and 1 in 8,000 girls worldwide.

Fragile X syndrome occurs when a single gene on the X chromosome shuts down. This gene makes a protein needed for normal brain development. In FXS it does not work properly, the protein is not made, and the brain does not develop as it should.

Learn more about Fragile X syndrome

How Does FRAXA Help?

FRAXA’s mission is to find effective treatments and ultimately a cure for Fragile X syndrome. We directly fund research grants and fellowships at top universities around the world. We partner with biomedical and pharmaceutical companies, large and small, to bridge the gap between research discoveries and actual treatments.

Treatments for Fragile X are likely to help people affected by autism, Alzheimer’s, and other brain disorders.

Donate to FRAXA's mission

Latest Fragile X News & Updates

View all News & Updates

FRAXA’s Most Successful End-Of-Year Campaign Ever!

FRAXA Research Foundation relies on the generosity of others to make our shared dream a reality. Our 2021 annual appeal was FRAXA’s most successful end-of-year campaign EVER! Together we will find effective treatments and ultimately a cure for Fragile X syndrome.
Read more

Neurodevelopmental Drug Development Summit Presentation

FRAXA president and co-founder, Katie Clapp was one of three patient advocacy leaders invited to kick off the Neurodevelopmental Drug Development Summit with a presentation on Fragile X, and FRAXA Scientific Advisor, Dr. Elizabeth Berry-Kravis also presented lessons learned from clinical trials in Fragile X Syndrome.
Read more

Reactivating the Fragile X Gene in Young Mice Reverses Symptoms

A new FRAXA-funded research project offers hope that Fragile X syndrome could be treated by reactivating the gene which is shut down in people with the syndrome. Researchers at the University of California, Riverside report that they were able to reduce FXS symptoms by inserting the FMR1 gene into the brains of very young mice.
Read more

10 Year Vision for Collaborations That Transform Fragile X and Autism Research

The future offers hope for people living with Fragile X syndrome. Collaborations between the Fragile X community and other disability organizations help to provide understanding and advancement of research to bring effective treatments to families. FRAXA's Dr. Mike Tranfaglia talks with Autism Science Foundation's Allison Singer about the importance of their collaboration as we look forward to the next 10 years.
Read more

Patrick’s PALS Still Shined Strong Even in the Face of COVID

Patrick's PALS 25th Annual 3-on-3 Basketball Tournament & Fundraiser was once again relegated to "Fundraiser Only" status in 2021. BUT, and it's a BIG but, the spirit, generosity and devotion of so many to this event still shined through. Over $140,000 was raised through a mail campaign, all of it of course going to FRAXA to continue to advance research that will someday lead to effective treatments and ultimately a cure.
Read more

$100,000 Donor Matching Challenge From The Robert & Ardis James Foundation

We are thrilled to announce FRAXA Research Foundation’s most significant and unique matching challenge of the year, thanks to the Robert & Ardis James Foundation. This challenge will help us bring top new talent to Fragile X research.
Read more